However, for the Brazilian government to be able to complete the acquisition of the vaccine, the vaccine, currently being tested at the Butantan Institute in Sao Paulo, will need to be submitted for approval to the National Health Surveillance Agency. (Anvisa).
According to the institute, the Chinese vaccine candidate would have displayed fewer adverse effects than all its competitors with a proportion of 35% of tests, against about 70% of tests with adverse effects for other vaccines, making it the vaccine the safer among those who have reached the final stages of testing.
AstraZeneca: dangerous vaccine candidate?
According to the Brazilian press, the Brazilian government estimates that the national vaccine program against covid-19 can start in January of next year, due to the delay caused by the candidate co-developed by the University of Oxford and AstraZeneca. A delay which pushed the government to conclude the agreement in question with the Chinese giant of the pharmaceutical industry.
By chance, one day before the agreement with Sinopharm was closed, a Brazilian doctor who had volunteered to test the vaccine developed by the University of Oxford and the AstraZeneca laboratory against Covid- 19, is deceased.
The National Health Surveillance Agency (Anvisa), under the Ministry of Health, said in a statement that it had been informed of the death on October 19 and that the independent committee monitoring this case suggested continuing studies and vaccine trials.
The agency did not say whether the volunteer had taken the vaccine or the placebo, in accordance with national and international good clinical practice regulations, which advocate confidentiality of data on clinical research volunteers.
A sinister event that comes as the Brazilian Ministry of Health planned to purchase 100 million doses of this vaccine for nearly $ 400 million, if studies confirm its effectiveness and safety.
Recall that the Minister of Health had declared the signing by his department of two partnership and cooperation agreements with the Chinese laboratory “Sinopharm”, aimed at involving the Kingdom in clinical trials of vaccination against the coronavirus and to ensure a sufficient stock. vaccines, in addition to a similar memorandum of understanding with the “AstraZeneca” group, through the Russian company “Ir-Farm”.